S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
NASDAQ:BCLI

Brainstorm Cell Therapeutics - BCLI Stock Forecast, Price & News

$3.50
+0.55 (+18.64%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.96
$3.54
50-Day Range
$2.55
$3.50
52-Week Range
$2.52
$4.46
Volume
367,856 shs
Average Volume
58,534 shs
Market Capitalization
$127.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Brainstorm Cell Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
2.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.94mentions of Brainstorm Cell Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.61) to ($0.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

974th out of 1,135 stocks

Biological Products, Except Diagnostic Industry

155th out of 180 stocks

BCLI stock logo

About Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Brainstorm Cell Therapeutics Price Performance

Shares of NASDAQ:BCLI traded up $0.55 during trading on Friday, hitting $3.50. 367,856 shares of the stock were exchanged, compared to its average volume of 58,534. Brainstorm Cell Therapeutics has a 1-year low of $2.52 and a 1-year high of $4.46. The company's fifty day simple moving average is $2.79 and its 200-day simple moving average is $3.01.

Brainstorm Cell Therapeutics (NASDAQ:BCLI - Get Rating) last posted its quarterly earnings results on Monday, May 16th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). During the same period in the previous year, the business posted ($0.19) EPS. Sell-side analysts predict that Brainstorm Cell Therapeutics will post -0.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics in a research note on Wednesday. They issued a "hold" rating on the stock.

Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCLI Stock News Headlines

Brainstorm Cell Earnings Preview
See More Headlines
Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCLI Company Calendar

Last Earnings
5/16/2022
Today
8/14/2022
Next Earnings (Estimated)
8/18/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCLI
Fax
N/A
Employees
43
Year Founded
N/A

Profitability

Net Income
$-24,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.53 per share

Miscellaneous

Free Float
28,809,000
Market Cap
$127.72 million
Optionable
Optionable
Beta
0.05

Key Executives

  • Mr. Chaim Lebovits (Age 51)
    Chief Exec. Officer
    Comp: $1.02M
  • Dr. Irit Arbel DSc (Age 62)
    Ph.D., Co-Founder & Independent Vice Chair of the Board
  • Dr. Ralph Z. Kern (Age 64)
    Pres & Chief Medical Officer
    Comp: $812.86k
  • Dr. Stacy R. Lindborg Ph.D. (Age 51)
    Exec. VP & Chief Devel. Officer
    Comp: $736.68k
  • Mr. Uri Yablonka (Age 45)
    Exec. VP, Chief Bus. Officer, Sec. & Director
  • Ms. Alla Patlis CPA (Age 35)
    M.B.A., Controller & Interim CFO
  • Dr. David Setboun M.B.A. (Age 47)
    Pharm.D., Exec. VP & COO
  • Dr. Yael Gothelf
    VP of Scientific & Regulatory Affairs
  • Ms. Antal Pearl-Lendner
    VP & Chief Legal Counsel
  • Dr. Daniel Offen Ph.D.
    Chief Scientific Advisor













BCLI Stock - Frequently Asked Questions

Should I buy or sell Brainstorm Cell Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BCLI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCLI, but not buy additional shares or sell existing shares.
View BCLI analyst ratings
or view top-rated stocks.

How have BCLI shares performed in 2022?

Brainstorm Cell Therapeutics' stock was trading at $4.00 at the start of the year. Since then, BCLI stock has decreased by 12.5% and is now trading at $3.50.
View the best growth stocks for 2022 here
.

When is Brainstorm Cell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 18th 2022.
View our BCLI earnings forecast
.

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) posted its quarterly earnings results on Monday, May, 16th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.02. During the same period in the previous year, the company earned ($0.19) EPS.

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

Who are Brainstorm Cell Therapeutics' major shareholders?

Brainstorm Cell Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Ikarian Capital LLC (0.69%), JPMorgan Chase & Co. (0.51%), Weaver Consulting Group (0.29%), S.C. Financial Services Inc. (0.07%), Virtu Financial LLC (0.06%) and Renaissance Technologies LLC (0.05%). Insiders that own company stock include David Setboun, International Holdings Ltd Acc, Irit Arbel, Preetam Shah, Ralph Dr Kern and Sankesh Abbhi.
View institutional ownership trends
.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Brainstorm Cell Therapeutics' stock price today?

One share of BCLI stock can currently be purchased for approximately $3.50.

How much money does Brainstorm Cell Therapeutics make?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) has a market capitalization of $127.72 million. The biotechnology company earns $-24,460,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

How can I contact Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.brainstorm-cell.com. The biotechnology company can be reached via phone at (201) 488-0460 or via email at pshah@brainstorm-cell.com.

This page (NASDAQ:BCLI) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.